PharmaResearch Products (PRP) Co., Ltd. of Korea has announced that it acquired CLEVIEL® assets from Aestura, a subsidiary of Amore Pacific, and currently seeks a partnership to introduce CLEVIEL® outside of South Korea. CLEVIEL®, the hyaluronic acid-based dermal filler, developed in Aestura, is the most viscous, elastic and cohesive dermal filler in the world and it provides surgeons a safe and better option for facial augmentations.
“We believe CLEVIEL® ideally complements the existing hyaluronic acid-based dermal fillers with substantially improved physical properties” said Mr. Kang, Executive Director of Business Development at PRP. He stated that CLEVIEL® Contour (50mg/mL) will provide a memorable experience to patients who desire for an assured contouring with just the right amount of HA. “CLEVIEL® will definitely satisfy both patients and surgeons.”
CLEVIEL® is currently classified as a medical device. It has been fully developed and patented by Amore Pacific, which leads the vogue for Korean cosmetics worldwide, now commercialized in South Korea, Japan and Hong Kong. Containing 50 mg/mL of cross-linked hyaluronic acid, CLEVIEL® shows high-lifting, low-spreading and contouring properties by the highest elasticity, viscosity and cohesiveness among other commercially available products. Due to these properties and ease in molding, CLEVIEL® is popularly known as a ‘Nose Filler’ to improve nose shape including nose tip and bridge. “We are planning to launch the series of CLEVIEL® brand with differentiated properties targeting the forehead, cheek, nasolabial folds and chin” said Mr. Kang.
CLEVIEL®’s own two strategies put more emphasis on conformity to quality standard. The hyaluronic acid used to manufacture CLEVIEL® is controlled by the most stringent specifications, which are only implemented for ophthalmic products. Therefore, CLEVIEL® has successfully dispelled the burden of endotoxins and impurities while hyaluronic acid content increases. The proprietary cross-linking technology also eliminates the free and incomplete cross-linking agent, which is toxic to the skin.
CLEVIEL®’s patent is currently filed in the United States, Europe, Japan, China and Hong Kong. “We have prepared the protective measurement of CLEVIEL® for our potential partners. Based on this confidence, we look forward to establishing a strategic partnership in order to nail down our position in the aesthetic industry with CLEVIEL® and other upcoming products” said Mr. Kang.
For any partnership inquiries, please contact to email@example.com
PRP, also known as the Pharma Research Products Company Limited, is a listed, middle-standing, yet rapidly growing, Korean pharmaceutical company dedicated to the development and commercialization of aesthetic medical devices and cosmetics. PRP developed and launched polynucleotide-based dermal filler and cosmetics, REJURAN® and REJURAN Healer®, PRP has recently completed 2 major M&A deals of adding hyaluronic acid dermal filler and botulinum toxin to accomplish the goal of providing a total facial aesthetics. With the synergy of existing products, PRP will provide an integrated and unique beauty solution to customers worldwide.